FibroBiologics, Inc. - Common Stock (NQ:FBLG)

1.440 +0.020 (+1.41%)

Streaming Delayed Price Updated: 11:00 AM EDT, Apr 8, 2026 Add to My Watchlist

Price and Volume

Volume	120,780
Open	1.420
Bid (Size)	1.420 (1,000)
Ask (Size)	1.460 (400)
Prev. Close	1.420
Today's Range	1.350 - 1.470
52wk Range	0.1850 - 3.965
Shares Outstanding	38,262,586
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

FibroBiologics Announces Closing of $3 Million Public Offering

April 02, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

Which stocks are moving before the opening bell on Wednesday? ↗

April 01, 2026

Via Chartmill

Performance

YTD	+500.3%	+500.3%
1 Month	+259.8%	+259.8%
3 Month	+453.8%	+453.8%
6 Month	+193.6%	+193.6%
1 Year	+65.5%	+65.5%

More News

FibroBiologics Announces Pricing of $3 Million Public Offering

March 31, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

Top movers in Tuesday's after hours session ↗

March 31, 2026

Via Chartmill

FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

March 31, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

March 31, 2026

Via Chartmill

Which stocks are experiencing notable movement on Tuesday? ↗

March 31, 2026

Via Chartmill

The market is filled with gapping stocks in Tuesday's session. ↗

March 31, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

March 25, 2026

Via Chartmill

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement

March 25, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed

March 18, 2026

From USA News Group

Via GlobeNewswire

FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

March 12, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

March 05, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

March 02, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics to Present at the BIO Investment & Growth Summit

February 26, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

February 24, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Granted Extension by Nasdaq to Regain Compliance

February 23, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

Get insights into the top gainers and losers of Wednesday's after-hours session. ↗

February 18, 2026

Via Chartmill

FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University

February 10, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia

February 05, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics to Present at the DealFlow Discovery Conference

January 20, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics CEO Issues Letter to Shareholders

January 07, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference

January 06, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

January 05, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

December 31, 2025

From FibroBiologics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is FibroBiologics, Inc. - Common Stock publicly traded?

Yes, FibroBiologics, Inc. - Common Stock is publicly traded.

What exchange does FibroBiologics, Inc. - Common Stock trade on?

FibroBiologics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for FibroBiologics, Inc. - Common Stock?

The ticker symbol for FibroBiologics, Inc. - Common Stock is FBLG on the Nasdaq Stock Market

What is the current price of FibroBiologics, Inc. - Common Stock?

The current price of FibroBiologics, Inc. - Common Stock is 1.440

When was FibroBiologics, Inc. - Common Stock last traded?

The last trade of FibroBiologics, Inc. - Common Stock was at 04/08/26 11:00 AM ET

What is the market capitalization of FibroBiologics, Inc. - Common Stock?

The market capitalization of FibroBiologics, Inc. - Common Stock is 55.10M

How many shares of FibroBiologics, Inc. - Common Stock are outstanding?

FibroBiologics, Inc. - Common Stock has 55M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.